Evidence map›Paper›PMID 31747605›Full record

ArticleCell reports2019

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.

Justin H Hwang, Ji-Heui Seo, Michael L Beshiri, Stephanie Wankowicz, David Liu, Alexander Cheung, Ji Li, Xintao Qiu, Andrew L Hong, Ginevra Botta and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 77 citations in OpenAlex.

  1. Xanthatin Attenuates Angiotensin II-Induced Cardiac Hypertrophy by Targeting CREB5.Journal of cardiovascular translational research · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 4 institutions in 1 country.

Justin H HwangDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Ji-Heui SeoDana-Farber Cancer Institute, Boston, MA, USA.
Michael L BeshiriLaboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Stephanie WankowiczDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
David LiuDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexander CheungDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Ji LiDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Xintao QiuDana-Farber Cancer Institute, Boston, MA, USA.
Andrew L HongDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Ginevra BottaBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Lior GolumbDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Camden RichterDana-Farber Cancer Institute, Boston, MA, USA.
Jonathan SoDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Gabriel J SandovalDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Andrew O GiacomelliDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Seav Huong LyDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Celine HanDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Chao DaiDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Hubert PakulaDana-Farber Cancer Institute, Boston, MA, USA.
Anjali SheahanDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Federica PiccioniBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Ole GjoerupDana-Farber Cancer Institute, Boston, MA, USA.
Massimo LodaDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Adam G SowalskyLaboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Leigh EllisDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.
Henry LongDana-Farber Cancer Institute, Boston, MA, USA.
David E RootBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Kathleen KellyLaboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Eliezer M Van AllenDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew L FreedmanDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Atish D ChoudhuryDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
William C HahnDana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA, USA; Brigham and Women's Hospital, Boston, MA, USA. Electronic address: william_hahn@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBroad Institute · USCenter for Cancer Research · USNational Cancer Institute · US

Funding

The Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8M
Resistance to Emerging Androgen Deprivation Therapies in Prostate CancerK08CA188615 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2014 to 2017
$708k
NCI NIH HHS K08 CA188615NCI NIH HHS U01 CA176058
6 · The paper itself

Abstract

Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open reading frame (ORF) expression screen and in tumor xenografts. CREB5 overexpression is essential for an enzalutamide-resistant patient-derived organoid. In AR-expressing prostate cancer cells, CREB5 interactions enhance AR activity at a subset of promoters and enhancers upon enzalutamide treatment, including MYC and genes involved in the cell cycle. In mCRPC, we found recurrent amplification and overexpression of CREB5. Our observations identify CREB5 as one mechanism that drives resistance to AR antagonists in prostate cancers.

Indexed as

Androgen Receptor AntagonistsAntineoplastic AgentsBenzamidesCyclic AMP Response Element-Binding Protein ADrug Resistance, NeoplasmHumansMaleNitrilesOpen Reading FramesPhenylthiohydantoinPromoter Regions, GeneticProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAndrogen Receptor AntagonistsAntineoplastic AgentsBenzamidesCREB5 protein, humanCyclic AMP Response Element-Binding Protein AenzalutamideNitrilesPhenylthiohydantoinReceptors, Androgenandrogen deprivation therapyandrogen receptorCREB5metastatic castration-resistant prostate cancerORF screentherapy resistance

Identifiers

PMID31747605
PMCPMC6886683
OpenAlexW2991319487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.